Erratum to clinical characteristics and prognostic factors of low metastatic burden prostate cancer with non-regional lymph node metastases: role of cytoreductive radiotherapy?
Erratum to: Transl Androl Urol 2025;14:228-39.
In the published article entitled “Clinical characteristics and prognostic factors of low metastatic burden prostate cancer with non-regional lymph node metastases: role of cytoreductive radiotherapy?” (1), the funding information was reported incorrectly as published. Therefore, the funding information should be corrected as follows:
Funding: This study was supported by the National Natural Science Foundation of China (Nos. 82102988 and 82303954) and the Guangdong Basic and Applied Basic Research Foundation (No. 2023A1515010391).
The authors regretted the error and confirmed this error did not significantly affect either the results or the conclusions of the paper.
Click here to view the updated version of the article.
Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.
References
- Mai L, Liu R, Zhang X, et al. Clinical characteristics and prognostic factors of low metastatic burden prostate cancer with non-regional lymph node metastases: role of cytoreductive radiotherapy? Transl Androl Urol 2025;14:228-39. [Crossref] [PubMed]
